Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.

Xiaowen Ding,Wenju Mo,Xiaohong Xie,Ouchen Wang,Yuqin Ding,Shuai Zhao,Xiangming He,Weiliang Feng,Dehong Zou,Hongjian Yang

Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.

2021

Xiaowen Ding
Wenju Mo
Xiaohong Xie
Ouchen Wang
Yuqin Ding
Shuai Zhao
Xiangming He
Weiliang Feng
Dehong Zou
Hongjian Yang

574Background: Pyrotinib is a new irreversible tyrosine kinase inhibitor (TKI) which significantly improved the progression-free survival (PFS) of patients with HER2+ metastatic breast cancer (MBC)...

Keywords:

Tyrosine-kinase inhibitor
Medicine
Internal medicine
Oncology
Neoadjuvant therapy
Metastatic breast cancer
Breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations